Divergent HLA Allele Linked to Immunotherapy Efficacy
Researchers uncover how immune checkpoint inhibitor response relies on the evolved efficiency of HLA-mediated immunity
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1616 results
FDA Approves Luspatercept-aamt for Anaemia in Patients with Beta Thalassemia
Evidence for efficacy is based on the results from the BELIEVE trial
Cancer-Related Cognitive Impairment in Cancer Survivors
Detection and management strategies
Crizotinib in c-MET- or ROS1-positive Non-Small Cell Lung Cancer
The results of the AcSé phase II study
Efficacy and Biomarker Analysis of Neoadjuvant Immune Checkpoint Blockade in Urothelial Cancer
Findings from the ABACUS trial
Gilteritinib for Relapsed or Refractory FLT3-Mutated AML
Results from the phase III randomised trial
Pembrolizumab as a Combination or Monotherapy in First-line Treatment for Recurrent or Metastatic HNSCC
The results from KEYNOTE-048 study
Discovery of AMG 510, a First in Class Oral KRAS G12C Inhibitor
Preclinical evidence and anti-tumour activity in the first dosing cohorts in patients with KRAS G12C mutated cancer
EMA Guide on Biosimilars for Healthcare Professionals Available Now in 23 Official EU Languages
The guide is updated in October 2019
Phase I/II Study Results with Lorlatinib in ROS1-positive Advanced NSCLC
Clinical activity observed even in patients with CNS metastases and those previously treated with crizotinib
Women Report More Adverse Drug Reactions Than Men
Higher proportion of serious and fatal adverse drug reactions reported among males
FDA Approves Niraparib for HRD-positive Advanced Ovarian Cancer
FDA also approved the Myriad myChoice CDx test for determination of tumour HRD status to select patients for niraparib